Leerink Swann Starts Hyperion Therapeutics (HPTX) at Outperform; Attractive Opportunity in Orphan Drug Model
Tweet
Share
E-mailGet Alerts HPTX Hot Sheet
Price: $45.99 --0%
Rating Summary:
3 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 11 | New: 6
Rating Summary:
3 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 11 | New: 6
Join SI Premium – FREE
Leerink Swann initiates coverage on Hyperion Therapeutics (NASDAQ: HPTX) with a Outperform. PT $18.00.
Analyst, Michael Schmidt, said, "Ravicti has a similar mechanism of action to Medicis' (NYSE: MRX) FDA-approved Buphenyl, the use of which is constrained by a large dose burden, frequent (3-6 times/day) administration, unpleasant taste and smell, tolerability issues, and high sodium content. Easier patient compliance to Ravicti therapy may enable better disease management ultimately translating into fewer hyperammonemic (HA) crises relative to what is currently available with Buphenyl. The rate of HA crises with Ravicti was 40% lower than that seen for Buphenyl in the 12-month safety extension study following HPTX's pivotal Phase III trial."
"In contrast to Salix Pharmaceuticals' (Nasdaq: SLXP) Xifaxan, which blocks nitrogen absorption in the gut for HE patients, Ravicti lowers ammonia systemically by increasing its clearance. Ravicti could thus potentially be complementary to currently approved agents that limit the local production of ammonia."
For an analyst ratings summary and ratings history on Hyperion Therapeutics click here. For more ratings news on Hyperion Therapeutics click here.
Shares of Hyperion Therapeutics closed at $10.04 yesterday.
Analyst, Michael Schmidt, said, "Ravicti has a similar mechanism of action to Medicis' (NYSE: MRX) FDA-approved Buphenyl, the use of which is constrained by a large dose burden, frequent (3-6 times/day) administration, unpleasant taste and smell, tolerability issues, and high sodium content. Easier patient compliance to Ravicti therapy may enable better disease management ultimately translating into fewer hyperammonemic (HA) crises relative to what is currently available with Buphenyl. The rate of HA crises with Ravicti was 40% lower than that seen for Buphenyl in the 12-month safety extension study following HPTX's pivotal Phase III trial."
"In contrast to Salix Pharmaceuticals' (Nasdaq: SLXP) Xifaxan, which blocks nitrogen absorption in the gut for HE patients, Ravicti lowers ammonia systemically by increasing its clearance. Ravicti could thus potentially be complementary to currently approved agents that limit the local production of ammonia."
For an analyst ratings summary and ratings history on Hyperion Therapeutics click here. For more ratings news on Hyperion Therapeutics click here.
Shares of Hyperion Therapeutics closed at $10.04 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Intermediate Capital Group (ICP:LN) (ICGUF) PT Raised to GBP22.50 at Citi
- Craig-Hallum Assumes DiaMedica Therapeutics Inc. (DMAC) at Buy
- Wells Fargo Starts Americold Realty Trust (COLD) at Equal Weight
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
